[go: up one dir, main page]

CY1116757T1 - Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη - Google Patents

Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη

Info

Publication number
CY1116757T1
CY1116757T1 CY20151100883T CY151100883T CY1116757T1 CY 1116757 T1 CY1116757 T1 CY 1116757T1 CY 20151100883 T CY20151100883 T CY 20151100883T CY 151100883 T CY151100883 T CY 151100883T CY 1116757 T1 CY1116757 T1 CY 1116757T1
Authority
CY
Cyprus
Prior art keywords
insulin
polypeptides
factor
growth factor
peptides
Prior art date
Application number
CY20151100883T
Other languages
English (en)
Inventor
Michael Diem
Karen O'neil
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of CY1116757T1 publication Critical patent/CY1116757T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Αποκαλυπτόμενα είναι πεπτίδια που προσδένουν τον υποδοχέα ομοιάζοντος με ινσουλίνη αυξητικού παράγοντα 1, και τα πολυνουκλεοτίδια που κωδικεύουν τα πολυπεπτίδια. Αποκαλυπτόμενες ακόμη είναι μέθοδοι για παραγωγή των πολυπεπτιδίων χρησιμοποιώντας συστήματα κυτταρικής έκφρασης και συστήματα άνευ κυττάρων και μέθοδοι χρήσης των πολυπεπτιδίων για παραγωγή πρωτεϊνών σύντηξης. Τα πολυπεπτίδια που αποκαλύπτονται μπορούν να παρέχουν μέσα για παράδοση θεραπευτικών παραγόντων διαμέσου του αιματοεγκεφαλικού φραγμού (ΒΒΒ).
CY20151100883T 2010-05-27 2015-10-05 Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη CY1116757T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34893710P 2010-05-27 2010-05-27
EP11787324.0A EP2575846B1 (en) 2010-05-27 2011-05-25 Insulin-like growth factor 1 receptor binding peptides

Publications (1)

Publication Number Publication Date
CY1116757T1 true CY1116757T1 (el) 2017-03-15

Family

ID=45004356

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100883T CY1116757T1 (el) 2010-05-27 2015-10-05 Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη

Country Status (27)

Country Link
US (1) US8415306B2 (el)
EP (1) EP2575846B1 (el)
JP (1) JP5864556B2 (el)
KR (1) KR101898502B1 (el)
CN (1) CN103025341B (el)
AU (1) AU2011258301B2 (el)
BR (1) BR112012030084B1 (el)
CA (1) CA2800744C (el)
CY (1) CY1116757T1 (el)
DK (1) DK2575846T3 (el)
EA (1) EA023541B1 (el)
ES (1) ES2550040T3 (el)
HR (1) HRP20151084T1 (el)
HU (1) HUE026269T2 (el)
IL (1) IL223030A (el)
ME (1) ME02206B (el)
MX (1) MX337134B (el)
NZ (1) NZ603611A (el)
PL (1) PL2575846T3 (el)
PT (1) PT2575846E (el)
RS (1) RS54278B1 (el)
SG (1) SG186068A1 (el)
SI (1) SI2575846T1 (el)
SM (1) SMT201500222B (el)
UA (1) UA107596C2 (el)
WO (1) WO2011150061A1 (el)
ZA (1) ZA201209689B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377421B (es) * 2014-03-06 2025-03-10 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
EA035517B1 (ru) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CN106559993B (zh) 2014-03-06 2020-12-15 加拿大国家研究委员会 胰岛素样生长因子1受体特异性抗体及其用途
KR101706296B1 (ko) 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
EP3255055B1 (en) 2015-12-21 2024-06-05 BrainOn Inc. Composition for improving memory, learning ability and cognition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
JPH06228199A (ja) * 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
EP1006184A1 (en) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
WO2001007084A1 (en) * 1999-07-23 2001-02-01 Regents Of The University Of California Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery
ES2275561T3 (es) 1999-10-04 2007-06-16 Nektar Therapeutics Al, Corporation Neuropeptidos estabilizados por polimeros.
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2004517816A (ja) * 2000-09-26 2004-06-17 ジェネンテック・インコーポレーテッド Ｉｇｅレセプターアンタゴニスト
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2003220557A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
JP2010538012A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Ｉｇｆ−１ｒの複数のエピトープに結合する組成物
CN101970730A (zh) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法

Also Published As

Publication number Publication date
KR20130111237A (ko) 2013-10-10
RS54278B1 (sr) 2016-02-29
BR112012030084B1 (pt) 2020-04-14
SMT201500222B (it) 2015-10-30
JP5864556B2 (ja) 2016-02-17
CA2800744C (en) 2018-09-04
UA107596C2 (uk) 2015-01-26
HK1183234A1 (zh) 2013-12-20
KR101898502B1 (ko) 2018-09-13
SI2575846T1 (sl) 2015-09-30
ME02206B (me) 2016-02-20
AU2011258301B2 (en) 2013-11-21
NZ603611A (en) 2014-12-24
PT2575846E (pt) 2015-09-16
SG186068A1 (en) 2013-01-30
US8415306B2 (en) 2013-04-09
CA2800744A1 (en) 2011-12-01
JP2013534811A (ja) 2013-09-09
CN103025341B (zh) 2015-07-22
EA201291416A1 (ru) 2013-06-28
PL2575846T3 (pl) 2015-12-31
HUE026269T2 (en) 2016-06-28
AU2011258301A1 (en) 2012-12-06
CN103025341A (zh) 2013-04-03
BR112012030084A2 (pt) 2017-06-20
US20110294748A1 (en) 2011-12-01
DK2575846T3 (en) 2015-08-10
IL223030A (en) 2016-11-30
HRP20151084T1 (hr) 2015-11-06
ZA201209689B (en) 2014-05-28
ES2550040T3 (es) 2015-11-04
IL223030A0 (en) 2013-02-03
EP2575846B1 (en) 2015-07-15
MX337134B (es) 2016-02-12
EP2575846A1 (en) 2013-04-10
MX2012013710A (es) 2013-05-20
EA023541B1 (ru) 2016-06-30
EP2575846A4 (en) 2013-12-11
WO2011150061A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CY1116757T1 (el) Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη
CY1124525T1 (el) Προσδετες τροποποιημενοι με κυκλικη μεταθεση ως αγωνιστες και ανταγωνιστες
CY1124888T1 (el) Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc και μεθοδοι χρησεως αυτων
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
CY1120319T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α
CY1122274T1 (el) Συνθεσεις και μεθοδοι για ενεργοποιηση σηματοδοτησης εξαρτωμενης απο «διεγερτη γονιδιου ιντερφερονης»
MY171407A (en) New polypeptides
NZ703581A (en) Anti-cd70 antibody drug conjugates
EA201600141A1 (ru) Терапевтический слитый белок
PH12015500977A1 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
MX2018013546A (es) Proteinas de fusion de elp para liberacion controlada y sostenida.
MX2008002101A (es) Fusiones de la proteina-1 quimiotactica de monocito.
CR20130112A (es) Polipéptidos que enlazan miostatina, composiciones y métodos
GT200900229A (es) Coagonistas de receptor de glucagón/glp-1
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
WO2012065055A3 (en) Fusion proteins for hiv therapy
IN2015DN02577A (el)
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
WO2014052451A3 (en) Insulin analog dimers
DK2007885T3 (da) Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider